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Abstract
Importance—Chemotherapy may result in a detrimental effect on ovarian function and fertility 
in premenopausal women undergoing curative treatment for early breast cancer (EBC). For this 
subgroup of patients, a careful consideration for techniques to minimize this risk should be given 
and the role of gonadotropin-releasing hormone agonists (GnRHa) for protection of ovarian 
function is not fully resolved.
Objective—To determine efficacy of GnRHa administered concurrently with chemotherapy for 
ovarian function preservation.
Data sources—The search for studies published between 1975 and March/2015 encompassed 
PubMed, SCOPUS and Cochrane databases, as well as ASCO Annual Meeting and San Antonio 
Breast Cancer Symposium abstracts.
Study selection—Prospective, randomized, controlled trials addressing the role of ovarian 
suppression with GnRHa in preventing early ovarian dysfunction in premenopausal women 
undergoing treatment for EBC were selected.
Data extraction and synthesis—Data extraction was performed independently by two 
authors. The methodology and the risk of bias were assessment based on the description of 
randomization method, withdrawals and blinding process.
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Main Outcomes Measures—Rate of resumption of regular menses after a minimal follow-up 
period of 6 months following chemotherapy was used as surrogate to assess the incidence of 
ovarian dysfunction. Additional secondary outcomes included hormone levels and number of 
pregnancies. Risk ratio estimates were calculated based on the number of evaluable patients. 
Analyses were conducted using a random effect model.
Results—Seven studies were selected, totaling 1047 randomized patients (856 evaluable 
patients).. The use of GnRHa was associated with a higher rate of recovery of regular menses after 
6 months (OR = 2.41; 95% CI 1.40–4.15; p= 0. 002) and at least 12 months (OR 1.85; 95% CI 
1.33–2.59; p = 0.0003) following last chemotherapy cycle. The use of GnRHa was also associated 
with a higher number of pregnancies (OR 1.85; 95% IC 1.02–3.36; p=0.04), although this outcome 
was not uniformly reported.
Conclusions and Relevance—GnRHa given with chemotherapy resulted in increased rates of 
recovery of regular menses and should be considered an option for ovarian function preservation 
in young women undergoing treatment for EBC. Additional outcomes related to ovarian function 
and fertility need to be further investigated.
Introduction
Breast cancer is among the leading causes of cancer-related mortality and the most common 
cancer in women worldwide (1). Significant improvements in survival have been achieved 
with the widespread use of adjuvant therapies in early-stage breast cancer (breast cancer that 
has not spread beyond the breast or the axillary lymph nodes) (EBC)(2). However, 
approximately 25% of the cases occur in premenopausal women, including 12% in women 
between the ages of 20 and 44 (3). For this subgroup of patients at reproductive age, the use 
of adjuvant chemotherapy with curative intent is associated with a risk of ovarian 
dysfunction, permanent or transient amenorrhea, infertility and symptoms of menopause 
with a premature onset (4). In addition to complications that include osteoporosis, loss of 
libido, increased cardiovascular risk and atrophic vaginitis, early ovarian dysfunction may 
adversely impact quality of life and result in significant psychosocial burden (4, 5).
Several series suggest that the incidence of ovarian dysfunction in women undergoing 
systemic treatment for EBC ranges widely from 4–90% and is influenced by chemotherapies 
used, duration of exposure, total dose, definitions applied and patients’ age (6–9). The latter 
represents the strongest predictor of ovarian dysfunction, with a significantly increased 
incidence over the age of 40 (10–12). Rates of chemotherapy-related amenorrhea and 
ovarian dysfunction following treatment with cyclophosphamide, methotrexate and 5-
fluorouracil (CMF) were 76%–100% in women aged 40 years and over in comparison to 
21%–70% in women under 40 (8, 13–15). Increased risk results from regimens containing 
high cumulative doses of alkylators and anthracyclines (16). In trials investigating 
combinations of fluorouracil, epirubicin and cyclophosphamide (FEC), chemotherapy-
induced menopause occurred in up to 60% of the patients (17), with similar incidences 
observed with taxane-containing regimens (16, 18, 19).
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The mechanism involved in ovarian damage is unclear, but may be linked to apoptotic 
oocyte death in primordial follicles entering the differentiation stage, which is particularly 
vulnerable to chemotherapy effects (20).
Pre-clinical studies suggested that hormonal suppression of the hypothalamic-pituitary-
ovarian axis could minimize the impact of cytotoxic agents over ovarian function (21–23). 
Based on this concept, several uncontrolled trials have been conducted to evaluate the 
activity of luteinizing-hormone releasing-hormone (LHRH) analogs/gonadotropin-releasing 
hormone agonists (GnRHa) in preventing the loss of ovarian function due to exposure to 
cytotoxic agents (24–26). In these studies, the proportion of patients who recovered ovarian 
function following concurrent ovarian suppression with GnRHa and adjuvant chemotherapy 
ranged from 72% to 96%. Nevertheless, final conclusions are confounded by heterogeneity 
of treatments used, outcomes assessed and lack of a control groups. A meta-analysis of 3 
randomized and 8 nonrandomized prospective controlled studies, 10 of which involved 
patients with diseases other than EBC, showed that GnRHa administered during 
chemotherapy are associated with a greater likelihood of maintaining ovarian function after 
treatment (OR 10.57; 95% CI, 5.22 to 21.39). Nonetheless, statistical significance was lost 
when only the randomized studies were considered (OR 5.76; 95% CI, 0.47 to 71.03) (27).
These findings prompted the development of randomized, controlled trials limited to a breast 
cancer population (28–37). The results, however, have been conflicting, and the role of 
GnRHa in the prevention of ovarian failure remains a question not fully resolved. Different 
meta-analyses suggest a benefit from ovarian suppression during chemotherapy in 
premenopausal women (38–44). However, these meta-analyses did not limit the population 
EBC patients or did not incorporate some of the largest studies in this setting, including the 
recently presented POEMS trial (36).
Guidelines from the American Society of Clinical Oncology (ASCO) recently updated 
recommend that patients with cancer who are at reproductive ages should be advised about 
the potential risks of fertility impairment and additional effects of chemotherapy and 
preservation techniques should be considered (45). However, “evidence regarding the 
effectiveness of ovarian suppression” is still quoted as “insufficient”.
Since standard strategies for fertility maintenance such as embryo and oocyte preservation 
techniques are associated with elevated costs, a potential risk of treatment delay and low 
success rates (46) and that currently few women receiving adjuvant chemotherapy undergo 
active approaches to preserve fertility and ovarian function (47), this is a topic of utmost 
importance. We aimed to conduct a meta-analysis to determine the role of ovarian 
suppression with GnRHa during chemotherapy in women undergoing treatment for EBC.
Materials and Methods
Search and selection criteria
A systematic review was performed for publications encompassing the following citation 
indexes: PubMed, SCOPUS and Cochrane Central Register of Controlled Trials, between 
1975 and March/2015, as well as the ASCO and San Antonio Breast Cancer Symposium 
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abstracts. The following medical subject headings/specific terms were used: “breast 
neoplasms”, “menopause, premature”, amenorrhea”, “gonadotropin-releasing hormone”, 
“goserelin”, “triptorelin”, “leuprolide”, “fertility”, “fertility preservation”, “chemotherapy, 
adjuvant”, “antineoplastic agents”, “clinical trial, randomized”. Additional searches were 
performed using key phrases “breast cancer AND ovarian dysfunction” or “chemotherapy 
induced amenorrhea”. The reference lists of all relevant articles were also reviewed.
Publications with the following criteria were selected: prospective, randomized, controlled 
trials addressing the role of ovarian suppression with GnRHa in preventing early ovarian 
dysfunction in premenopausal women undergoing curative chemotherapy for EBC. No 
restrictions concerning the definition or characterization of the primary endpoints were made 
for the study selection. Uncontrolled studies and those using strategies other than GnRHa for 
preventing early menopause were excluded, as were incomplete trials and those with unclear 
definitions of ovarian dysfunction or follow up inferior to 6 months.
Data extraction
Two authors selected the studies according to the previously described criteria and extracted 
all data independently. In cases of discrepancies during the selection process or data 
extraction, consensus was achieved following discussions. An identification number was 
provided to each of the selected trials, allowing for a blind review. Unpublished trials and 
those for which additional information was not provided were allowed if adequate data 
extraction was possible..
Eligible endpoints to address ovarian dysfunction (main outcome) included resumption of 
regular menses after a minimal follow-up period of 6 months and after 12–24 months 
following chemotherapy, encompassing different definitions of “regular menses” used across 
studies. Follicle-stimulating hormone (FSH) and estradiol (E2) concentrations were also 
investigated. Restoration of fertility, rates of pregnancy/successful delivery and sonographic 
description of the ovaries were not considered valid endpoints for main analyses due to the 
high probability of confounding factors, but exploratory analyses were performed if 
available data.
Analysis and synthesis
Methodology and the risk of bias were evaluated using the criteria suggested by Jadad et al. 
(48), with assessment of the randomization method, withdrawals and blinding process.
Risk ratio estimates were calculated for the dichotomous outcomes with a 95% confidence 
interval for the estimation of the effect of the administration of GnRHa given concurrently 
with chemotherapy versus no ovarian suppression. Outcome measures were estimated 
according to the number of evaluable treated patients, and not the intention to treat 
population. Analyses were conducted using a random effect model. The heterogeneity 
between the risk ratios for the same outcome between different studies was assessed using 
the chi-square-based Q statistic, with significance at a P value of less than 0.10, and 
expressed in I2 index.
Statistical analyses were performed with RevMan5.1 software.
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Results
Database search returned 603 entries; 592 were excluded after initial review. Primarily 
excluded publications included reviews, retrospective studies, letters, trials addressing the 
anticancer activity of GnRHa, duplicate results and uncontrolled trials. Among the 
remaining 11 studies, reasons for exclusion are as follows. One trial corresponded to pre-
planned sub-protocol of a trial addressing the antitumoral effect of GnRHa. Goserelin was 
administered for 2 years, with or without tamoxifen, irrespectively of the hormone receptor 
status; hence, the prolonged duration of treatment with tamoxifen could affect by itself the 
assessment of amenorrhea at 6 months and 12–24 months [31]. One trial that did not report 
the outcomes of interest and was also excluded (49) (Figure 1). One randomized trial had 
inconsistencies in the study methods and reporting of results, and was therefore excluded 
(50). Of the eight potentially eligible studies, one was presented in abstract form only (34) 
with insufficient data for the main analyses. (Figure 1). The author was contacted, but no 
additional information was provided.
Seven trials published in full met the predefined criteria and were included in the analysis, 
totaling 1047 randomized/856 evaluable patients aged between 18–49 years (28–30, 32, 35–
37). Of note, long-term outcomes of the PROMISE-GIM6 study by Del Mastro et al. were 
presented as abstract only (51); therefore, the original publication was selected for data 
extraction [30] and for referencing across the manuscript. The characteristics of the studies 
are summarized in Table 1.
Although eligibility criteria varied, all studies required the patients to be premenopausal at 
enrollment, defined as prior history of cyclic menstrual bleedings/regular menses, with 
(28,29, 32, 36, 37) or without (30, 35) premenopausal hormone levels at baseline. Ovarian 
suppression was induced with goserelin, triptorelin or leuprolide, beginning at least one 
week before the first cycle of chemotherapy and maintained until the last cycle in 6 out of 7 
trials. In the trial by Elgindy et al., simultaneous commencement of the GnRHa and 
chemotherapy was allowed, but patients received concurrent GnRH antagonist (cetrorelix 
acetate) until suppression of estradiol levels (35). Anthracycline and cyclophosphamide-
based regimens were administered to over 90% of the patients; a smaller proportion of 
patients also received taxanes. Treatment characteristics are summarized in Table 1.
GnRHa and recovery of menses
The administration of GnRHa (goserelin, triptorelin or leuprolide) was associated with a 
higher rate of recovery of regular menses after a minimum of 6 months after the last cycle of 
chemotherapy in premenopausal women receiving treatment for early stage breast cancer 
(OR = 2.41; 95% CI 1.40–4.15; p= 0.002; Figure 2A), although a high heterogeneity among 
trials was observed (I2 = 58%; p= 0.03).
The rate of recovery of regular menses in the control groups increased uniformly with time 
and this endpoint was reached after a median of 5 to 6.1 months in at least two of the 
included trials (28, 29). As a result, we hypothesized that measuring the outcomes at 6 
months could be inadequate. Therefore, an additional analysis was performed, including 
only the rates of menses resumption after a minimum interval of 12 months since last 
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chemotherapy cycle. When the analysis was limited to trials with a minimum follow up of 
12 months, GnRHa resulted in a statistically significant improvement in the rate of 
resumption of menses, with no heterogeneity among trials (OR 1.85; 95% CI 1.33–2.59; p = 
0.0003; I2 = 0%. Figure 2B).
We also aimed at performing a time-to-event analysis comparing the mean time to recovery 
of menses in patients treated with GnRHa and controls. However, this comparison was 
hampered by incomplete data.
GnRHa and hormone levels
Complete data to evaluate the impact of GnRHa on hormone serum concentrations were not 
consistently described and, therefore, this analysis was not performed. In the trial by Badawi 
et al., patients treated with GnRHa showed lower FSH (p<0.009) and higher E2 (p<0.001) 
levels when compared to the control group (32). In the trial by Gerber et al., only 17/60 
patients were accessible for hormone measurements (29). In the trial by Del Mastro et al. 
FSH/E2 measurements were not available for approximately 30% of the patients (30). In the 
trial by Song et al., although the mean values of E2 were similar between groups at 12 
months after the end of chemotherapy, significantly higher values of FSH were reported in 
patients treated with chemotherapy only (p<0.05) (37). No statistically significant 
differences in FSH and additional hormone levels were identified in two additional studies 
(28, 35).
GnRHa and pregnancies
The use of GnRHa was also associated with a higher number of pregnancies (OR 1.85; 95% 
IC 1.02–3.36; p=0.04). However, pregnancy outcomes and the total number of attempted 
pregnancies was not uniformly reported across trials and fertility/rate of pregnancies were 
not the primary endpoint in any of the studies. In addition, in the trial by Moore et al, 
patients with incomplete data and therefore not evaluable for the primary endpoint were still 
included in pregnancy outcomes (total number of evaluable patients for pregnancies: 113 in 
the control arm/105 in the GnRHa arm) (36).
Discussion
Chemotherapy-induced early menopause and its impact on quality of life is a pragmatic and 
clinically important topic that often arises during the treatment with curative intent of 
premenopausal patients with EBC. The present meta-analysis of RCT showed that the 
addition of a GnRHa during chemotherapy, given in the neoadjuvant or adjuvant setting, was 
associated with ovarian function preservation as assessed by the rate of recovery of regular 
menses in young women with EBC.
Alternative methods for preserving fertility, including embryo/oocyte cryopreservation, 
ovarian transposition and ovarian tissue transplantation, can be time-consuming and costly. 
Moreover, some of these techniques are unable to prevent negative effects of early 
menopause, including loss of bone density, increased cardiovascular risk and vasomotor 
symptoms. In our study, the main outcome used as a surrogate for ovarian function was 
resumption of regular menses. Based on the current World Health Organization definition, 
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which defines menopause as the absence of menstrual periods for 12 months, our findings 
suggest that goserelin, triptorelin or leuprolide are effective in preventing chemotherapy-
induced premature menopause in young women with EBC (OR 1.85; p = 0.0003).
Major concerns when evaluating effects of chemotherapy on fertility and menopause are the 
discrepant definitions of ovarian dysfunction used. This heterogeneous characterization of 
outcomes is, in part, responsible for the wide variability in the incidence of ovarian 
dysfunction (8, 16, 52–54). Resumption of regular menses, however, is a clinically relevant 
and reproducible outcome. It should be noted, nevertheless, that recovery of menses does not 
necessarily translate into subsequent fertility restoration and that better biomarkers of 
ovarian function, including Inhibin and anti-Müllerian hormone, are of clinical interest.
In our meta-analysis, high heterogeneity among trials (I2=65%) was observed after first 
efficacy analysis after a minimal follow up of 6 months, which could be attributable to two 
determinant aspects: age of the patients and time to outcome measurement. Age 
independently has an impact on the risk of permanent menopause and could be associated 
with efficacy of GnRHa (16, 54). The trial by Badawy et al included patients aged 40 or less, 
with a median age of 30 years, versus 37–39 years in most of the remaining trials; this 
younger patient population could account for a higher likelihood of recovery of ovarian 
function. The fears of a negative effect over the childbearing potential is increased at 
younger ages and even younger women who restore their menses will still experience 
premature menopause as a delayed effect. This could represent a subgroup of patients of 
greater interest and for whom a positive effective on ovarian protection could be associated 
with meaningful improvements. None of the trials evaluated the long-term ovarian reserve 
and the onset of premature menopause after temporary amenorrhea, and longer follow up is 
necessary to address this issue. Moreover, the likelihood of resuming ovarian function 
decreases as a woman approaches the mean age of natural menopause and GnRHa could 
have only a marginal effect in older patients. However, the cut-off to select patients for 
whom ovarian suppression is of clinical relevance is still unknown.
GnRHa were given concurrently with the standard regimens recommended for the neo-/
adjuvant treatment of EBC. Noteworthy, more than 90% of the included patients received 
anthracycline-based combinations and a significant proportion received taxanes. Therefore, 
it is unlikely that the conflicting efficacy results could be attributable to different drug 
combinations with distinct potential for ovarian damage.
There has been concern that the restoration of ovarian function could negatively impact 
long-term outcomes of patients with EBC due to a possible stimulating effect on quiescent 
hormone-sensitive tumor cells. In the National Surgical Adjuvant Breast and Bowel Project 
(NSABP) B-30 trial, women with prolonged amenorrhea showed improved disease-free 
survival and overall survival after adjustment for both tumor and treatment related variables 
(55) and this was also suggested by other authors (56, 57). In fact, some of the trials 
included in this meta-analysis excluded patients with positive expression of estrogen (ER) 
and progesterone receptors (PR) (29, 35, 36). However, the true impact of amenorrhea as an 
independent prognostic factor and the benefits of re-introducing GnRHa in this subgroup of 
patients is still under investigation. Moreover, breast cancer in younger patients has different 
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clinicopathological characteristics, with a high incidence of hormone-receptor negative 
tumors (58), for whom the restoration of ovarian function could have little, if any, impact on 
survival. In fact, concurrent administration of GnRHa resulted in longer disease-free survival 
and overall survival in the POEMS trial, restricted to patients with ER/PR-negative tumors 
(HR=0.49, p=0.04; HR=0.43, p=0.05, respectively)(36). Furthermore, long-term results of 
the PROMISE-GIM6 trial support the safety of GnRHa even in hormone-sensitive patients, 
in which 81% of the patients had ER/PR-positive tumors. After a median follow-up of 7.3 
years, no differences in the 5-year disease-free survival were observed (83.7% in 
chemotherapy alone arm versus 80.5% in CT plus GnRHa; p=0.519) (51).
Several limitations should be highlighted. Despite the extensive search, only seven studies 
met the predefined criteria, leading to a limited number of patients, 44% of which were 
derived from two studies (30)(37). The data extracted for the analysis were retrieved from 
published articles and abstracts; we did not have access to individual patient data. Hence, the 
characterization of “regular menses” was not uniform and the numbers used for these 
analyses reflect the outcomes as assessed by each investigator, as detailed in Table 1. 
Furthermore, the effect of additional confounding factors affecting the ovarian function and 
efficacy of GnRHa (examples include body mass index, concurrent endocrine/auto-immune 
diseases, specific age groups etc.) could not be assessed. Some of the included trials were 
discontinued prematurely and had incomplete analyses of outcomes relevant for a thorough 
assessment of ovarian function, including hormone levels, restoration of ovulation, rates of 
pregnancies etc. Another limitation was the lack of detailed survival outcomes, which led 
this meta-analysis not to address a possible interaction between GnRHa and long-term 
results. In addition, although a higher number of pregnancies was also observed in the 
intervention arm, this was not statistically significant and it’s important to highlight that 
most of the trials did not report the total number of attempted pregnancies and were not 
formally designed to address fertility outcomes, which could lead to significant bias 
associated with imbalance between treatment groups, and the true impact of GnRHa in 
fertility remains unclear. Although similar meta-analyses have been published (38–44), this 
is the first to encompass the largest and most recent trials reported to date, consequently 
including a larger number of individuals and providing more robust estimates of the benefit 
of GnRHa specifically for patients undergoing treatment for EBC.
Even though this was not the scope of the present study, side effects associated with GnRHa 
must also be weighted, and include hot flashes, vaginal dryness, headache and, rarely, 
thromboembolic events. Although not uniformly reported, side effects resulting from 
GnRHa were tolerable and had little impact in the overall toxicity. For example, only 7% of 
the patients in the trial by Moore et al. experienced grade 3/4 adverse events in the group 
treated with goserelin, versus 5% in the control arm (36). In the trial by Del Mastro et al., 
rates of hot flushes, headache, sweating, mood modification and vaginal dryness were not 
statistically different between the treatment arms (30). In the phase II study by Song et al., 
adverse events attributed to leuprolide were of grade 1 or 2 only (37).
Currently available guidelines consider the use of GnRHa as experimental. This study 
provides evidence suggesting that GnRHa given concurrently with chemotherapy to 
premenopausal patients undergoing treatment for EBC are effective tools to prevent early 
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menopause and this strategy could be incorporated into clinical practice. Nevertheless, 
additional outcomes related to ovarian function and fertility need to be further investigated.
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Figure 1. 
Search process
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Figure 2. 
Impact of GnRH – Resumption of regular menses and pregnancies.
Forest plots: (A) Menses resumption after 6 months among evaluable patients; (B) Menses 
resumption after 12–24 months among evaluable patients.
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